Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design.

Interventional clinical trials for patients with HGG have substantial heterogeneity regarding eligibility criteria pertaining to bevacizumab use, demonstrating a need for standardizing clinical trial design.